Literature DB >> 7977077

Cardiac dysfunction late after cardiotoxic therapy for childhood cancer.

J Leandro1, J Dyck, D Poppe, R Shore, C Airhart, M Greenberg, D Gilday, J Smallhorn, L Benson.   

Abstract

Despite a wealth of data documenting acute cardiac injury from anthracycline therapy and/or mediastinal radiotherapy used for childhood cancer, little information is available on the long-term consequence of these insults. Twenty-nine patients (mean age 15 +/- 4.3 years) from The Late Effects Follow-Up Clinic For Childhood Cancer study, who had been in continuous, complete remission and off chemotherapy for a minimum of 2 years (mean follow-up 7.2 +/- 3.2) were studied. All patients had normal ejection fractions before and during cancer therapy and all were in New York Heart Association class I at the time of study. Systolic and diastolic functions were assessed by 2-dimensional echocardiography, Doppler flow velocity, and radionuclide angiography, and results were compared with normal control subjects. Left ventricular mass and mass index were significantly reduced in the patient population. Fractional shortening was decreased overall and end-systolic wall stress was much higher in patients than in controls. However, contractility, as assessed by the relation of wall stress to rate-corrected velocity of shortening, was decreased by > or = 2 SDs in only 6 of 28 patients, and the force-mass relation was actually increased in the patient group as a whole. Mitral valve inflow velocities were significantly increased but the pattern was abnormal. These results suggest a pattern consistent with a thin-walled, complaint left ventricle with reduced muscle mass performing under above-normal levels of wall stress. Contractility measurements were normal or increased in the group, but some patients clearly demonstrated development of reduced contractile function.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977077     DOI: 10.1016/0002-9149(94)90470-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

Authors:  James C Lightfoot; Ralph B D'Agostino; Craig A Hamilton; Jennifer Jordan; Frank M Torti; Nancy D Kock; James Jordan; Susan Workman; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2010-07-09       Impact factor: 7.792

2.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

3.  The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer.

Authors:  Lubomir Elbl; Hana Hrstkova; Vaclav Chaloupka
Journal:  Eur J Pediatr       Date:  2003-08-07       Impact factor: 3.183

4.  Cardiac function in long-term survivors of childhood lymphoma.

Authors:  Mark K Friedberg; Ido Solt; Myriam Weyl-Ben-Arush; Yulia Braver; Avraham Lorber
Journal:  Cardiol Res Pract       Date:  2011-01-20       Impact factor: 1.866

5.  Review of cardiotoxicity in pediatric cancer patients: during and after therapy.

Authors:  Joy M Fulbright
Journal:  Cardiol Res Pract       Date:  2011-05-23       Impact factor: 1.866

6.  Cardiac damage after treatment of childhood cancer: a long-term follow-up.

Authors:  Veronika Velensek; Uros Mazic; Ciril Krzisnik; Damjan Demsar; Janez Jazbec; Berta Jereb
Journal:  BMC Cancer       Date:  2008-05-20       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.